Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?

被引：4
|
作者：
Dicembrini, Ilaria [1 ]
Mannucci, Edoardo [1 ]
机构：
[1] Careggi Teaching Hosp, Diabetol, Florence, Italy
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 184卷
关键词：
Type; 2; diabetes; Myocardial infarction; Dipeptidyl Peptidase 4 inhibitors; METAANALYSIS;
D O I：
10.1016/j.ijcard.2015.02.034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：543 / 544
页数：2
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
    Fu, Jianying
    Zhu, Jianhong
    Hao, Yehua
    Guo, Chongchong
    Zhou, Zhikun
    SCIENTIFIC REPORTS, 2016, 6
  • [22] The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Kanasaki, Keizo
    CLINICAL SCIENCE, 2018, 132 (04) : 489 - 507
  • [23] Dipeptidyl Peptidase-4 inhibitors and risk of inflammatory bowel disease: Real world evidence in US adults
    Wang, Tiansheng
    Yang, Jeff Y.
    Buse, John B.
    Pate, Virginia
    Tang, Huilin
    Barnes, Edward
    Sandler, Robert S.
    Sturmer, Til
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 225 - 225
  • [24] Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho, Y.
    Itoh, H.
    DIABETIC MEDICINE, 2013, 30 (04) : e149 - e150
  • [25] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
    Rankovic, Marina
    Jeremic, Nevena
    Srejovic, Ivan
    Radonjic, Katarina
    Stojanovic, Aleksandra
    Glisic, Milos
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    HEART FAILURE REVIEWS, 2021, 26 (02) : 437 - 450
  • [26] Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
    Makino, Yuichi
    Fujita, Yukihiro
    Haneda, Masakazu
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (01): : 67 - 73
  • [27] Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
    Monami, Matteo
    Dicembrini, Ilaria
    Martelli, Daniele
    Mannucci, Edoardo
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 : 57 - 64
  • [28] Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
    Larry K. Golightly
    Caitlin C. Drayna
    Michael T. McDermott
    Clinical Pharmacokinetics, 2012, 51 (8) : 501 - 514
  • [29] Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
    Shoombuatong, Watshara
    Prachayasittikul, Veda
    Anuwongcharoen, Nuttapat
    Songtawee, Napat
    Monnor, Teerawat
    Prachayasittikul, Supaluk
    Prachayasittikul, Virapong
    Nantasenamat, Chanin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4515 - 4549
  • [30] Effect of dipeptidyl peptidase-4 inhibitors on complement activation
    Hoffmann-Petersen, Ingeborg T.
    Holt, Charlotte B.
    Jensen, Lisbeth
    Hage, Camilla
    Mellbin, Linda G.
    Thiel, Steffen
    Hansen, Troels K.
    Ostergaard, Jakob A.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2021, 37 (03)
12345